Everbright Health has launched an AI-enabled platform designed to enhance the identification, engagement, and management of patients eligible for advanced mental health treatments. This innovative system aims to address the significant gap in care for individuals with treatment-resistant mental health conditions by providing mental health providers with actionable data to facilitate access to options like transcranial magnetic stimulation (TMS) and SPRAVATO®. The platform is particularly crucial given that nearly 60 million Americans suffer from mental illness, with over 15 million experiencing serious mental illness (SMI) that often does not respond to standard treatments.

The significance of this development lies in its potential to double treatment outcomes compared to traditional medication and therapy alone. Everbright’s platform not only identifies eligible patients but also assists providers in navigating complex prior authorizations and billing workflows. This approach mitigates operational barriers that have historically hindered the implementation of advanced interventions, ensuring that a greater proportion of patients receive the care they need. CEO Ben Kuhn emphasized that over one-third of patients in typical mental health practices qualify for these advanced treatments, yet many are overlooked due to manual eligibility assessments.

The implication of Everbright Health’s platform is profound, as it shifts the paradigm of mental health care from a predominantly medication-based model to one that integrates advanced therapeutic options into everyday practice. This transition could significantly accelerate the timeline for drug development and clinical integration of advanced mental health interventions, ultimately leading to improved patient outcomes and a more efficient healthcare system. By leveraging AI to streamline processes, Everbright is poised to redefine how mental health providers deliver care to those with treatment-resistant conditions.

Source: globenewswire.com